Global Industry Analysts, Inc., Feb 2011, Pages: 349
& Reporting Level 3
Quantitative Techniques & Analytics 3
Product Definitions and Scope of Study 3
2. MARKET OVERVIEW 4
Biosimilars - The New Pharma Industry's Dynamite 4
European Union Ahead of the US 4
Business Insights, Nov 2005
containment and reimbursement
Biogenerics
Development of sales and marketing capabilities
Complex regulations
Analyst perception and access to funding
Public perception/ethics
Chapter 4 Biotech growth
Global Industry Analysts, Inc., Oct 2011, Pages: 749
of drugs with superior efficacy keep growth prospects optimistic. Companies engaged in the development of new drugs continue to rely on superior efficacy, expansion of indications and convenient mode of drug
Arrowhead Publishers, Dec 2006, Pages: 348
: Genentech
2.3.1 New Methods of Protein Manufacture
2.3.1.1 Transgenic Animal Production
2.3.1.2 Protein Pharming
2.3.1.3 Transgenic Plant Production
2.4 The Biogeneric Threat
2.4.1 Loss of Patent Protection
2
Informa Healthcare, Jan 2007, Pages: 237
the new opportunities presented by this market trend, as well as its challenges.
With regulation playing a key role in the evolving landscape for biosimilar products, the report places particular emphasis
Bioplan Associates Inc., Nov 2008, Pages: 415
– technologies invented in the 1970s and commercialized in the 1980s.
Who Should Read this Book?:
Whether you are a large or small innovator, CMO or biogenerics company and seek to develop new licensing/income
